(MENAFN- GlobeNewsWire - Nasdaq) With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results